

**UNITED STATES OF AMERICA**  
**Before the**  
**SECURITIES AND EXCHANGE COMMISSION**

**SECURITIES EXCHANGE ACT OF 1934**  
**Release No. 88846 / May 11, 2020**

The U.S. Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the "Exchange Act"), of trading of the securities of Bioscience Neutraceuticals, Inc. ("Bioscience") (OTC: DEVV), of Chicago, Illinois, at 9:30 a.m. EDT on May 11, 2020, and terminating at 11:59 p.m. EDT on May 22, 2020.

The Commission temporarily suspended trading in the securities of Bioscience because of questions that have been raised about the accuracy and adequacy of publicly disseminated information concerning, among other things, questions relating to Bioscience's apparent lack of business activity and an e-mail stock promotion from an unknown source directed to investors which claimed a potential for continued appreciation in the price of Bioscience's stock based solely on its past market performance. There are also questions about (a) the lack of shareholder transparency, and (b) the recent trading activity in the securities of Bioscience including substantial selling of Bioscience's stock by a single account. This order was entered pursuant to Section 12(k) of the Exchange Act.

The Commission cautions brokers, dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.

Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not he has complied with the rule, he should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he should refrain from entering quotations relating to Bioscience's securities until such time as he has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation that is in violation of the rule, the Commission will consider the need for prompt enforcement action. The SEC appreciates the assistance of the Financial Industry Regulatory Authority (FINRA).

If any broker, dealer or other person has any information that may relate to this matter, they should immediately contact Amy Gwiazda, Assistant Director, at (617) 573-8839, or John Dugan, Associate Director, at (617) 573-8936.

